Partners keep Bavencio ball rolling at ASCO

5 June 2018

The pressure for companies with cancer assets to come to the party at the American Society of Clinical Oncology (ASCO) Annual Meeting with impressive data presentations is real – and there is a feeling that those that do not steal the show have to present a picture of progress just to keep pace.

German drugmaker Merck KGaA (MRK: DE) and US pharma giant Pfizer (NYSE: PFE) have certainly achieved the latter with their updated efficacy and safety data from the JAVELIN Merkel 200 trial of Bavencio (avelumab) in patients with metastatic Merkel cell carcinoma (mMCC).

"Chemotherapy has historically been the only treatment option for this devastating disease"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK